(NASDAQ: ANIP) Ani Pharmaceuticals's forecast annual revenue growth rate of 12.85% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.66%.
Ani Pharmaceuticals's revenue in 2024 is $538,953,000.On average, 3 Wall Street analysts forecast ANIP's revenue for 2024 to be $12,396,539,209, with the lowest ANIP revenue forecast at $12,351,027,671, and the highest ANIP revenue forecast at $12,458,336,429. On average, 3 Wall Street analysts forecast ANIP's revenue for 2025 to be $15,080,373,336, with the lowest ANIP revenue forecast at $14,902,240,797, and the highest ANIP revenue forecast at $15,288,341,918.
In 2026, ANIP is forecast to generate $16,006,384,797 in revenue, with the lowest revenue forecast at $15,723,468,412 and the highest revenue forecast at $16,190,997,944.